news

Oct 10, 2024
Oct 8, 2024
Oct 2, 2024
Linkedin-in

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Pivotal study design aligned with FDA on streamlined pathway to NDA submission goal in 2024 Topline results anticipated late in 2Q 2024 SALT LAKE CITY, May 1, 2024 /PRNewswire/ — Lipocine Inc

Recent

Press

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Read More

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Read More

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Read More

Focus on enhancing health

We are pioneers of developing innovative drug products targeting significant unmet medical needs.